The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE).
 
Masatoshi Kudo
Honoraria - Bayer; Eisai
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Kowa; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Kowa (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Michihisa Moriguchi
Research Funding - Bayer; Bayer (Inst); Kowa; Kowa (Inst); Kyowa Hakko Kirin; Kyowa Hakko Kirin (Inst); Pfizer; Pfizer (Inst); Taiho Pharmaceutical; Taiho Pharmaceutical (Inst); Yakult Honsha; Yakult Honsha (Inst)
 
Kazushi Numata
Honoraria - Bayer; Daiichi Sankyo
Research Funding - Bayer (Inst); Eisai (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Hisashi Hidaka
Honoraria - Ajinomoto; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; Otsuka; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Ajinomoto (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Nihon Pharma (Inst); Otsuka (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hironori Tanaka
Honoraria - Bayer; Century Medical; Daiichi Sankyo; Philips Healthcare
Research Funding - Bayer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Masafumi Ikeda
Consulting or Advisory Role - NanoCarrier
Speakers' Bureau - Abbott Diagnostics; Bayer; Bristol-Myers Squibb Japan; Dainippon Sumitomo Pharma; Guerbet; Kyowa Hakko Kirin; Merck Serono; Novartis; Takeda; Yakult Honsha
Research Funding - AstraZeneca; AstraZeneca (Inst); Bayer; Bayer (Inst); Chugai Pharma; Chugai Pharma (Inst); Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma (Inst); Eisai; Eisai (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Kowa; Kowa (Inst); Kyowa Hakko Kirin; Kyowa Hakko Kirin (Inst); Lilly Japan; Lilly Japan (Inst); Merck Serono; Merck Serono (Inst); Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim (Inst); Novartis; Novartis (Inst); OncoTherapy Science; OncoTherapy Science (Inst); Ono Pharmaceutical; Ono Pharmaceutical (Inst); Otsuka; Otsuka (Inst); Pfizer; Pfizer (Inst); Taiho Pharmaceutical; Taiho Pharmaceutical (Inst); Yakult Honsha; Yakult Honsha (Inst); Zeria Pharmaceutical; Zeria Pharmaceutical (Inst)
 
Seiji Kawazoe
Honoraria - Otsuka
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Kowa (Inst); MSD (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shinichi Ohkawa
Honoraria - Daiichi Sankyo; Eisai; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Nippon Boehringer Ingelheim
Research Funding - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly Japan; OncoTherapy Science; Taiho Pharmaceutical; Yakult Honsha
 
Yozo Sato
Honoraria - Bayer; Daiichi Sankyo; Novartis
Consulting or Advisory Role - OncoTherapy Science
Research Funding - Eisai (Inst); Kyowa Hakko Kirin (Inst); Nippon Boehringer Ingelheim (Inst); Taiho Pharmaceutical (Inst)
 
Takuji Okusaka
Honoraria - Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly Japan; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca; Bayer; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; Nippon Boehringer Ingelheim; Novartis; OncoTherapy Science; Ono Pharmaceutical; Otsuka; Pfizer; Sceti Medical Labo; Shizuoka; Taiho Pharmaceutical; Takeda; Yakult Honsha